McCann Shaun R, Crampe Mireille, Molloy Karen, Lawler Mark
Department of Hematology, St James's Hospital/University of Dublin, Trinity College, Durkan Building, Trinity Center, Dublin 8, Ireland.
Transfus Apher Sci. 2005 Feb;32(1):55-61. doi: 10.1016/j.transci.2004.10.006.
Hematopoietic chimerism is a measure of the number of donor and recipient cells in the host following stem cell transplantation (SCT). The type of conditioning therapy prior to SCT has a major impact on the chimeric status in the recipient. Different techniques of measurement have varying sensitivities. The use of polymerase chain reaction (PCR) of short tandem repeats (STR) using fluorescent amplification permits quantification using Genescan analysis. When SCT is used for malignant haematological disorders, measurement of chimeric status may indicate early relapse and in aplastic anemia graft rejection. Reduced intensity or T-cell depletion is associated with mixed haemopoietic chimerism. SCT for benign haematological disorders does not require complete donor chimerism for a successful outcome.
造血嵌合体是干细胞移植（SCT）后宿主中供体细胞和受体细胞数量的一种度量。SCT前的预处理疗法类型对受体中的嵌合状态有重大影响。不同的测量技术具有不同的灵敏度。使用荧光扩增对短串联重复序列（STR）进行聚合酶链反应（PCR），可通过基因扫描分析进行定量。当SCT用于恶性血液系统疾病时，嵌合状态的测量可能提示早期复发以及再生障碍性贫血中的移植物排斥。减低强度预处理或T细胞清除与混合造血嵌合体相关。用于良性血液系统疾病的SCT并不需要完全的供体嵌合体就能获得成功结果。
